Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.08) by 63.89 percent. This is a 41.6 percent decrease over losses of $(1.25) per share from the same period last year. The company reported quarterly sales of $1.000 million which missed the analyst consensus estimate of $18.750 million by 94.67 percent.